1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Legacy Technology Holdings, Inc.

Legacy Technology Holdings, Inc.

LTHO
Legacy Technology Holdings, Inc.US flagOther OTC
0.00
USD
- -
- -
1,720.00Market Cap
Legacy Technology Holdings, Inc.
LTHO
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2005
2006
2007
2008
2009
2010
2011
2012
TTM
FRC
0.14
0.77
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-1.91
-0.78
-0.21
-0.01
-0.02
-0.03
-0.04
-0.05
-0.26
Basic EPS, GAAP
-1.39
-0.19
- -
-0.01
- -
- -
- -
- -
-0.02
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-1.91
-1.42
-1.59
-0.01
-0.05
-0.1
-0.14
-0.19
-0.42
Book Value per Share
-1.31
-0.92
-1.11
-0.15
-0.22
-0.41
-0.45
-0.5
-0.49
Tangible Book Value per Share
- -
1
1
9
7
4
4
4
4
Basic Weighted Avg Shares
- -
1
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
-1,040.6
-89.02
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-1
-1
- -
- -
- -
- -
- -
- -
-1
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-1,398.01
-101.06
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-1
-1
-1
-1
-2
-2
-2
-2
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
-1
-1
-1
-1
-2
-2
-2
-2
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'13
Jun'13
Sep'13
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
4
4
28
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Mar'13
Jun'13
Sep'13
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
2
2
2
Payables & Accruals
1
1
1
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
10.91%
10.54%
Free Cash Flow
- -
- -
-76.97%
Net Income, GAAP
- -
4.68%
28.68%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2011
- -
- -
- -
- -
- -
2012
- -
- -
- -
- -
- -
2013
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2011
-0.01
-0.01
-0.01
- -
-0.04
2012
-0.01
-0.01
-0.01
- -
-0.05
2013
-0.03
-0.01
-0.18
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2011
- -
- -
- -
- -
- -
2012
- -
- -
- -
- -
- -
2013
- -
- -
- -
- -
- -
Similar Companies
TPCO Holding Corp. (GRAMF)
SSY Group Limited (2005.HK)
SCI Pharmtech, Inc. (4119.TW)
Rockwell Medical, Inc. (RMTI)
Paion AG (PA8.F)
Beijing Aosaikang Pharmaceutical Co., Ltd. (002755.SZ)
Business
Legacy Technology Holdings, Inc. (LTHO) develops and commercializes web-based genomic preventative medicine and medical software solutions; it also functions as an investment holding company focused on hemp and hemp-related products and technologies. The company offers advanced technology systems integrating software and hardware tailored for healthcare, manufacturing, and logistics sectors, with an emphasis on sustainability, innovation, and digital transformation to enhance operational productivity. Founded in 2012 and headquartered at 7295 W. 62nd Ave., Arvada, Colorado 80003, United States, Legacy Technology Holdings operates primarily in the healthcare technology industry, serving global business clients through strategic partnerships and a distribution network. Previously operated as a nutraceutical marketing and distribution company acquiring intellectual property and processes, the firm maintains zero reported employees and trades on OTCPK with a minimal market capitalization. No major acquisitions, funding rounds, partnerships, or product launches reported in the last 1-2 years.